<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62898</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Psoriasis in plaques is a chronic disease that requires systemic treatment in its moderate and severe forms. Because the need for treatment is generally prolonged, many medications indicated for its treatment cannot be used continuously and have to be replaced by other different drugs, but also with a limited use, both due to their possible side effects, their teratogenicity, the time of use and accumulated dose, among other reasons. The biological drugs have been designed for middle and long term control of the disease. Efalizumab is a drug that has been shown to be effective and safe in patients who have moderate-to-severe psoriasis. We present our results in a group of 50 patients, our special cases, the form in which we have treated the side effects due to Efalizumab and those due to the disease (AU)</dc:description>
<dc:creator>Vázquez-Veiga, HA</dc:creator>
<dc:creator>Seoane-Pose, MJ</dc:creator>
<dc:creator>Fernández-Blanco, MT</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La psoriasis en placas es una enfermedad crónica que en sus formas moderadas y graves precisa tratamiento sistémico. La necesidad de tratamiento, generalmente prolongado, hace que muchos medicamentos indicados para el tratamiento de la psoriasis no puedan ser utilizados de forma continuada y tengan que ser sustituidos por otros fármacos diferentes pero también con un uso limitado, tanto por sus posibles efectos secundarios, como por su teratogenicidad, el tiempo de uso y la dosis acumulada, entre otros motivos. Los fármacos biológicos han sido diseñados para el control a medio y largo plazo de la enfermedad. Efalizumab es un medicamento que se ha demostrado eficaz y seguro en los pacientes que presentan una psoriasis moderada a grave. Presentamos nuestros resultados en un grupo de 50 pacientes, nuestros casos especiales, la forma en que hemos tratado los efectos secundarios debidos a efalizumab y los debidos a la enfermedad (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.1): 62-69, ene. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-62898</dc:identifier>
<dc:subject>^d12592^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6412^s22012</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d30914^s22012</dc:subject>
<dc:subject>^d23997^s22073</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d12137^s22045</dc:subject>
<dc:subject>^d30164^s22073</dc:subject>
<dc:subject>^d12002^s22080</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d10987^s22066</dc:subject>
<dc:subject>^d10987^s22045</dc:subject>
<dc:subject>^d9636^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200801</dc:date>
</metadata>
</record>
</ibecs-document>
